Heart Failure | Simplex Quantum

Same pathway, toward earlier diagnosis.

Heart failure is often missed for months, and too many patients are only diagnosed after an acute admission, even though every case passes through the same first point of care, specialist workup, and monitoring. Our AI ECG research is designed to surface that risk earlier, at those same stages, on whatever ECG or wearable is already in hand: acute or outpatient.

THE PATIENT JOURNEY TODAY

WHERE OUR AI COULD ACT

At risk

Stage A/B, asymptomatic

Symptoms begin

Often dismissed

Earlier

On a wearable, before any visit

Heart failure is often first identified in acute care, once symptoms have already become urgent. A possible future research direction: on-demand risk identification on a wearable for people who are at risk or starting to notice symptoms, before a first visit.

First Point of Care

Outpatient care

Acute admission

38% first diagnosed in acute care; where mortality is worse.^1,2

Access

On a 12-lead ECG, wherever that first ECG is

An echo is hard to get: it needs a referral first. A 12-lead ECG is already done immediately for anyone with heart symptoms, whether that's acute or outpatient care. Putting risk identification on that ECG could give access at the first point of contact, either way.

Specialist Workup

BNP/NT-proBNP

Echocardiogram

Diagnosis

Specialist workup itself doesn't change here — but as risk is flagged earlier upstream, the time it takes to reach an echo and a diagnosis is intended to shorten.

Median 40 days to echo. Only 29% diagnosed within a year.³

GDMT + monitoring

Treatment, then follow-up

Monitoring

On a wearable, after diagnosis

After a patient is diagnosed, a dedicated monitoring algorithm on a wearable could watch for early signs of decompensation between visits, flagging risk before it turns into a readmission.

25% readmitted within 30 days, and 63% within one year.⁴